Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

meningococcal B disease

- PMLiVE

Merck sees €2bn from new launches by 2022

Expects to deliver total sales of €4bn with multiple sclerosis, fertility and cancer drugs portfolio

Eli Lilly HQ

Lilly planning 20 new launches by 2023

Will focus on diabetes, immunology, oncology, neurodegeneration and pain

- PMLiVE

Searching for health

Janssen France’s Emmanuelle Quiles on finding ways to produce pharma innovations in a challenging environment

- PMLiVE

Niche-busting cancer immunotherapies

Targeted oncology treatments are a reason for hope

- PMLiVE

Developing therapeutic cancer vaccines

Dendreon’s success has paved the way for new candidates

- PMLiVE

A new option for people with HIV

ViiV Healthcare's dolutegravir could capture a significant share of the HIV market and may have blockbuster potential

- PMLiVE

Pipeline: Major depressive disorder therapeutics

There are limited pipeline prospects to address this significant health issue

- PMLiVE

Late-stage ovarian cancer

Novel treatment strategies have yielded several promising agents that have reached phase III

Bayer symbol

Bayer expects five drugs to enter phase III in 2015

Hopes to follow success of recent launches

- PMLiVE

Research into meningococcal B disease

The first approved vaccine represents a major success for meningococcal B research efforts

- PMLiVE

Chasing the cure for Parkinson’s disease

Research for this common neurodegenerative disease has made remarkable progress over the last decade, but current therapies can only reduce its symptoms

- PMLiVE

Upcoming treatments for amyotrophic lateral sclerosis

While some progress has been made in the treatment of ALS, combination therapies with drugs that target other pathways, alongside stem cell technology, are sorely needed

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links